Director, Launch Preparedness, Policy & Advocacy Strategy, and Execution Lead, non-MD

ROLE SUMMARY

The Launch Preparedness, Policy & Advocacy Strategy, and Execution Lead is a leadership role within the U.S. Vaccines Field Medical organization, accountable for launch preparedness, policy integration, advocacy strategy, and field medical readiness across priority vaccine and drug assets.

Reporting to the Vaccines National Accounts, Organized & Retail Customer, Policy Lead, this role provides senior‑level leadership for U.S. launch readiness and execution, ensuring that policy, access, coverage, and advocacy considerations are proactively anticipated and effectively integrated into field medical strategy, enablement, and deployment across the Vaccines portfolio. The role operates at individual contributor level, with an initial focus on the Lyme Vaccine (LB6V) and responsibility to support additional vaccine and drug launches as portfolio priorities evolve.

This role partners closely with Vaccines HQ Medical, Scientific Engagement Leads (SELs), Commercial leadership, Medical Analytics, Medical Engagement & Impact (MEI), National Accounts leadership, and external medical societies to ensure coordinated, policy‑informed, and field‑ready execution that supports successful launches and sustained adoption.

Serving as a principal strategic advisor to Vaccines Field Medical leadership, U.S. Medical Affairs Vaccines Policy, and cross‑functional partners, this role acts as a critical connector between HQ strategy and field medical execution. It plays a central leadership role in shaping launch readiness expectations, field engagement approaches, and medical execution models, with a strong emphasis on anticipating policy, coverage, and advocacy dynamics to enable effective launch preparation and sustained impact across the U.S. Vaccines portfolio.

ROLE RESPONSIBILITIES

Launch Preparedness & Execution

***(Initial Focus: Lyme Vaccine, LB6V; Broader Portfolio Scope)

• Set and govern national launch preparedness strategy and operating standards for priority U.S. vaccine and drug launches, with an initial focus on the Lyme Vaccine (LB6V) and flexibility to support additional assets as portfolio priorities evolve.

• Define, maintain, and govern enterprise‑wide launch readiness standards, success metrics, and policy‑related readiness expectations for Vaccines Field Medical, ensuring consistent application across assets and field teams.

• Serve as the escalation authority for policy‑driven risks and access barriers that may impact launch timing, uptake, or sustainability, providing strategic recommendations and decision support to U.S. Medical Affairs and Commercial leadership.

• Partner with HQ Brand Medical leads and cross‑functional stakeholders, including Commercial, Operations, Medical Analytics, and Vaccines Field Medical leadership, to anticipate and shape national field deployment models, engagement priorities, and enablement strategies, without duplicating asset‑level strategy ownership.

• Provide enterprise oversight and strategic direction for Pre‑Approval Information Exchange (PIE) readiness and execution, ensuring consistent governance, insight synthesis, and readiness expectations across launches.

• Leverage enterprise‑level medical insights, analytics, and engagement data to continuously refine launch preparedness frameworks and optimize field medical effectiveness at scale.

• Provide strategic oversight and direction for the development and deployment of launch‑related training, playbooks, and field readiness materials, ensuring alignment with enterprise standards and policy‑informed engagement expectations.

• Ensure scalable, repeatable, and policy‑integrated launch preparedness approaches are applied across pipeline and in‑line assets, rather than asset‑specific or ad hoc execution models.

Policy Strategy & Advocacy Execution

• Serve as the Field Medical Policy Lead for U.S. Vaccines, with enterprise accountability for how field medical policy and advocacy engagement is operationalized, in close alignment with, but distinct from, the U.S. Medical Affairs Vaccines Policy team, which retains ownership of policy development.

• Set national strategic direction for field medical policy and advocacy engagement models that support launch readiness, lifecycle management, and access outcomes across the Vaccines portfolio.

• Provide enterprise‑level oversight and guidance for field medical engagement with key medical societies that influence vaccine recommendations, clinical guidelines, and access, ensuring consistent national standards rather than individual asset approaches.

• Lead and shape enterprise field medical engagement across national organizations, including ACOG, AAP, IDSA, ACP, AAFP, and other rel